Aptose Riding Higher As The Street Starts Paying Attention

In a relatively short span of time, Aptose (APTO) has gone from a little-known Canadian biotech toiling largely in obscurity to a promising name with wider sell-side coverage. That expanded interest isn’t unreasonable in my view, as promising (but very early) data have made an initial case that Aptose might really have something special with its pan-FLT3/pan-BTK inhibitor CG-806 for hematological cancers.

There remains a long road between commercial success and today, though, and while I do think Aptose has made a strong case for how and why CG-806 is meaningfully better than other options both on the market and in the clinic, the fields of biotech are littered with the bodies of once-promising companies whose therapies were going to change the standard of care, but didn’t come through with the clinical data when it really mattered. I believe these shares are still worth owning today, but investors need to appreciate the well above-average risks that go with investing in early-stage biotech.

Read more here:
Aptose Riding Higher As The Street Starts Paying Attention